Mizuho set a $88.00 price target on Gilead Sciences (NASDAQ:GILD) in a research report report published on Friday. The firm currently has a buy rating on the biopharmaceutical company’s stock.
GILD has been the subject of several other research reports. Zacks Investment Research downgraded shares of Gilead Sciences from a hold rating to a sell rating in a report on Wednesday, January 23rd. ValuEngine upgraded shares of Gilead Sciences from a sell rating to a hold rating in a report on Saturday, December 1st. Citigroup reiterated a buy rating and issued a $100.00 target price on shares of Gilead Sciences in a report on Tuesday, February 5th. JPMorgan Chase & Co. reiterated a buy rating on shares of Gilead Sciences in a report on Thursday, March 7th. Finally, Maxim Group set a $84.00 target price on shares of Gilead Sciences and gave the company a buy rating in a report on Tuesday, February 5th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. Gilead Sciences has a consensus rating of Hold and an average target price of $82.29.
Shares of GILD stock traded down $1.15 on Friday, hitting $63.77. The stock had a trading volume of 5,911,778 shares, compared to its average volume of 7,420,952. The company has a market cap of $82.81 billion, a P/E ratio of 10.37, a P/E/G ratio of 4.09 and a beta of 1.16. The company has a debt-to-equity ratio of 1.19, a current ratio of 3.38 and a quick ratio of 3.30. Gilead Sciences has a 12-month low of $60.32 and a 12-month high of $79.61.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.70 by ($0.26). The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.52 billion. Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. The business’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.78 EPS. As a group, research analysts expect that Gilead Sciences will post 6.23 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 28th. Investors of record on Friday, March 15th will be given a dividend of $0.63 per share. The ex-dividend date is Thursday, March 14th. This represents a $2.52 annualized dividend and a yield of 3.95%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.57. Gilead Sciences’s dividend payout ratio is presently 40.98%.
In related news, Director John Francis Cogan sold 2,700 shares of the stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $65.07, for a total transaction of $175,689.00. Following the completion of the transaction, the director now owns 57,560 shares in the company, valued at $3,745,429.20. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Gayle E. Wilson sold 19,068 shares of the stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $67.08, for a total transaction of $1,279,081.44. Following the transaction, the director now owns 143,567 shares of the company’s stock, valued at approximately $9,630,474.36. The disclosure for this sale can be found here. 1.16% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of GILD. S&CO Inc. boosted its position in Gilead Sciences by 5.5% during the fourth quarter. S&CO Inc. now owns 6,325 shares of the biopharmaceutical company’s stock worth $396,000 after purchasing an additional 330 shares during the period. Addenda Capital Inc. boosted its position in Gilead Sciences by 2.3% during the fourth quarter. Addenda Capital Inc. now owns 59,731 shares of the biopharmaceutical company’s stock worth $3,735,000 after purchasing an additional 1,362 shares during the period. IMA Wealth Inc. boosted its position in Gilead Sciences by 31.6% during the fourth quarter. IMA Wealth Inc. now owns 7,121 shares of the biopharmaceutical company’s stock worth $445,000 after purchasing an additional 1,710 shares during the period. Clear Perspective Advisors LLC boosted its position in Gilead Sciences by 3.6% during the fourth quarter. Clear Perspective Advisors LLC now owns 8,680 shares of the biopharmaceutical company’s stock worth $543,000 after purchasing an additional 300 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in Gilead Sciences by 199,789.8% during the third quarter. Bank of New York Mellon Corp now owns 31,350,714 shares of the biopharmaceutical company’s stock worth $2,420,587,000 after purchasing an additional 31,335,030 shares during the period. Institutional investors own 79.13% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
Recommended Story: Earnings Per Share
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.